Work

Photobiomodulation (low-level laser therapy) for temporomandibular disorders: clinical efficacy, methodological quality, and dosimetric reporting — an umbrella review of systematic reviews and meta-analyses

Year: 2026
Type: article
Abstract: Background To synthesise, at the level of systematic reviews (SRs) and meta-analyses (MAs), the efficacy of photobiomodulation (PBM)/low-level laser therapy (LLLT) for temporomandibular disorders (TMD), and to appraise the corpus’s methodological quality (AMSTAR-2), primary-study overlap, and dosimetry reporting. Methods Umbrella review of SRs/MAs of PBM/LLLT for TMD (PROSPERO: CRD420261458816). Five databases (Epistemonikos, PubMed/MEDLINE, Lens.org, LILACS, SciELO) were searched from inception to 25 July 2026 without language restriction. Quality was appraised with AMSTAR-2, overlap via corrected covered area (CCA), and dosimetry against a checklist; synthesis was narrative, and certainty was rated with GRADE using the estimates reported by the source meta-analyses. Results Of 231 records, 136 were unique and 32 SRs/MAs met inclusion. Most pooled estimates favoured PBM for short-term pain and maximum mouth opening (MMO; e.g., pain SMD − 0.55, 95% CI − 0.82 to − 0.27, Hanna 2021; MMO MD + 2.78 mm, 1.12 to 4.44, Máximo 2022), but magnitude was highly heterogeneous (I² up to 99%) and metrics non-comparable. Of 30 appraisable, 21 were AMSTAR-2 “Critically Low”, 1 “High”; just 11/32 reported a registered protocol. Across 30 reviews with retrievable study lists, 180 primary trials underpinned the corpus (45% included in ≥ 2 reviews); overall overlap was slight (CCA 5.48%). Wavelength and schedule were reported by 94%, but power density/irradiance (41%) and energy/dose (44%) in fewer than half. Conclusions PBM/LLLT may reduce temporomandibular pain (low certainty, GRADE), but the evidence is very uncertain about the effect on short-term mouth opening (very low certainty), and harms were not assessed. The review-level evidence is numerous but shows only slight primary-study overlap, is mostly of critically low methodological quality, and is inconsistent in reporting delivered-dose parameters. Pre-registered trials that report complete dosimetry would allow future syntheses to estimate the effect and its dose dependence more reliably. Registration PROSPERO CRD420261458816.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7234797293
FWCI:
Cites:
Cited by:
Related to: 10